Ask AI
Bill116th CongressFiled Nov 18, 2019Commerce
H.R. 5133

Affordable Prescriptions for Patients Through Promoting Competition Act of 2019

Bill journey · stage 2 of 5

Under committee review

Filed
Comm.
Floor
Both
Law

What it doesSummary reported to house (Dec 24, 2020)

Affordable Prescriptions for Patients Through Promoting Competition Act of 2019

This bill prohibits, subject to certain exceptions, the practice of product hopping, which is presumed when a drug manufacturer obtains removal of a drug from the Food and Drug Administration's approved drug list, discontinues a drug, or markets a reformulation of an already approved drug during a certain period after which the manufacturer has been notified that a competing drug manufacturer has applied for generic drug approval.

What just happenedDec 24, 2020

Placed on the Union Calendar, Calendar No. 578.

Who’s behind it

Rep. Cicilline, David N. [D-RI-1](D-RI)Sponsor
5 cosponsors2 D3 R
Read on Congress.gov
5cosponsors1committees10actions3related bills12subjects
  1. Dec 24, 2020CalendarsH12410

    Placed on the Union Calendar, Calendar No. 578.

  2. Dec 24, 2020CommitteeH12200

    Reported by the Committee on Judiciary. H. Rept. 116-695.

    Judiciary Committee
  3. Dec 24, 2020Committee5000

    Reported by the Committee on Judiciary. H. Rept. 116-695.

    Judiciary Committee
  4. Nov 21, 2019Committee

    Ordered to be Reported.

    Judiciary Committee
  5. Nov 21, 2019Committee

    Committee Consideration and Mark-up Session Held.

    Judiciary Committee
  6. Nov 19, 2019Committee

    Subcommittee on Antitrust, Commercial, and Administrative Law Discharged.

    Judiciary Committee
  7. Nov 18, 2019IntroReferralH11100

    Referred to the House Committee on the Judiciary.

    Judiciary Committee
  8. Nov 18, 2019Committee

    Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.

    Administrative State, Regulatory Reform, and Antitrust Subcommittee
  9. Nov 18, 2019IntroReferralIntro-H

    Introduced in House

  10. Nov 18, 2019IntroReferral1000

    Introduced in House

Reported to HouseDec 24, 20207

Affordable Prescriptions for Patients Through Promoting Competition Act of 2019

This bill prohibits, subject to certain exceptions, the practice of product hopping, which is presumed when a drug manufacturer obtains removal of a drug from the Food and Drug Administration's approved drug list, discontinues a drug, or markets a reformulation of an already approved drug during a certain period after which the manufacturer has been notified that a competing drug manufacturer has applied for generic drug approval.

Introduced in HouseNov 18, 2019

Affordable Prescriptions for Patients Through Promoting Competition Act of 2019

This bill prohibits, subject to certain exceptions, the practice of product hopping, which is presumed when a drug manufacturer obtains removal of a drug from the Food and Drug Administration's approved drug list, discontinues a drug, or markets a reformulation of an already approved drug during a certain period after which the manufacturer has been notified that a competing drug manufacturer has applied for generic drug approval.

Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 — Informed